Showing results (71-80 of 137) with videos related to
Sort By:
Pageof 14
Cancers|December 17, 2024
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a SignatureMarco Filetti, Mario Occhipinti, Alessio Cirillo, et al.Translational Lung Cancer Research|July 18, 2020
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score systemArsela Prelaj, Claudia Proto, Giuseppe Lo Russo, et al.Tumori|June 24, 2026
Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patientsAndrea Vingiani, Alberta Piccolo, Adele Busico, et al.JTO Clinical and Research Reports|October 13, 2025
Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLCSun Min Lim, Ana Laura Ortega Granados, Gustavo Dix Junqueira Pinto, et al.ESMO Open|April 10, 2019
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitorsGiovanni Fucà, Giulia Galli, Marta Poggi, et al.Cancers|April 3, 2021
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic ProgressionArsela Prelaj, Chiara Carlotta Pircher, Giacomo Massa, et al.ESMO Open|May 30, 2020
LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trialClaudio Vernieri, Monica Ganzinelli, Eliana Rulli, et al.Journal of Personalized Medicine|June 2, 2021
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase InhibitorsMario Occhipinti, Marta Brambilla, Giulia Galli, et al.Future Oncology (London, England)|June 20, 2022
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapyEmma Zattarin, Sara Manglaviti, Giulia Apollonio, et al.Clinical Lung Cancer|February 23, 2021
Recent Advances in the Management of Typical and Atypical Lung CarcinoidsNatalie Prinzi, Roberta Elisa Rossi, Claudia Proto, et al.Pageof 14